Prognostic value of COMP a comparison with ACCP in rheumatoid arthritis patients in Iraq

Abstract

The study aimed To investigate prognostic ability of Cartilage oligomeric matrix protein (COMP)a comparison with Anti citrullinated peptide antibody (ACCP)and explore response to Methotrexate (MTX) , Etanercept and without treatment patients , with disease activity in rheumatoid arthritis Iraqi patients.Method of studywasCasecontrol. Measurement levels of biomarkersby ELISA.Results of ACCP and COMP levelsin RApatients highly significantly thanhealthy controlp< 0.001.highly significant ACCP and COMP levels in active diseasethan moderate and low activityp < 0.001 .Without treatments Patients ACCP and COMPlevels highly significant than onMTXor etanercept p<0.001, Statistically non-significant between on MTX andetanerceptp>0.05 .Significant positive correlation between ACCP and COMP(r =0.53,p<0.001) ACCP and CDAI (r =0.459,p < 0.001) COMP and CDAI(r =0.519, p<0.001) ACCP and COMP cutoff <)13.13 U / ml,< 0.21 ng / ml) Sensitivity (72 %,78 %) Specificity (98%,84%respectively).SuggestionCOMP has potential prognostic abilitya comparison with ACCPand to differentiation between RA patients andhealthyand predict severity of disease with response to MTX or etanercept.